Medicines Notices




3022

NEW ZEALAND GAZETTE

No. 101

Health

Medicines Act 1981

Corrigendum

In the notice published in the New Zealand Gazette, 16 December 1993, No. 181, page 3752, notice No. 10671, for the strength “200 mg/ml” in the seventeenth line, replace the strength “200 mg/5 ml”.

Dated this 26th day of September 1994.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

g07194

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Maprotiline hydrochloride 25 mg, 75 mg Tablets Merckle GmbH, Blaubeuren, Germany Mapylin
Levodopa 100 mg, carbidopa 25 mg Tablets Alphapharm Pty Limited, Carole Park, Brisbane, Queensland, Australia Sindopa
Cefpirome 250 mg, 500 mg, 1 g, 2 g (as the sulphate) Powder for reconstitution for iv injection Hoechst AG, Frankfurt am Main, Germany and Roussel Laboratories Limited, Swindon, Wiltshire, England Cefrom

Dated this 26th day of September 1994.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

g07192

Consent to the Distribution of Changed Medicines

Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Ranitidine 150 mg/10 ml (as the hydrochloride) Syrup Glaxo Operations UK Limited, Barnard Castle, County Durham, England; Glaxo Operations UK Limited, Speke, Liverpool, England and Glaxo Operations UK Limited, Ware, Hertfordshire, England Zantac
Ranitidine 150 mg, 300 mg (as the hydrochloride) Tablets Glaxo Operations UK Limited, Barnard Castle, County Durham, England; Glaxo Operations UK Limited, Ware, Hertfordshire, England; Glaxo Australia Pty Limited, Boronia, Victoria, Australia and Glaxo Pharmaceuticals Limited, Palmerston North Zantac
Ranitidine 150 mg, 300 mg (as the hydrochloride) Effervescent tablets Glaxo Operations UK Limited, Ware, Hertfordshire, England and Laboratoires Glaxo SA, Zone Industrielle No 2, Evreux, France Zantac
Ranitidine 150 mg, 300 mg (as the hydrochloride) Effervescent granules Glaxo Operations UK Limited, Ware, Hertfordshire, England and Laboratoires Glaxo SA, Zone Industrielle No 2, Evreux, France Zantac

Dated this 26th day of September 1994.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

g07193



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1994, No 101


NZLII PDF NZ Gazette 1994, No 101





✨ LLM interpretation of page content

🏥 Corrigendum to Medicines Notice

🏥 Health & Social Welfare
26 September 1994
Corrigendum, Medicines Act 1981, Strength Correction
  • C. Lovelace, Director-General of Health

🏥 Consent to Distribution of New Medicines

🏥 Health & Social Welfare
26 September 1994
Medicines Act 1981, New Medicines, Distribution Consent
  • C. Lovelace, Director-General of Health

🏥 Consent to Distribution of Changed Medicines

🏥 Health & Social Welfare
26 September 1994
Medicines Act 1981, Changed Medicines, Distribution Consent
  • C. Lovelace, Director-General of Health